Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB019
- Development stage
- Unknown
- Lead developer
- Ligand Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
SB019 is an investigational **intranasal small molecule antiviral** developed by Novan for the treatment of COVID-19 caused by SARS-CoV-2. It is an intranasal formulation of **berdazimer sodium**, a nitric oxide-releasing compound derived from Novan's NITRICIL platform. The therapeutic rationale is that local nitric oxide delivery in the nasal cavity can exert antiviral activity by disrupting viral protein function and inhibiting viral replication, thereby potentially reducing infection and transmission. Publicly described data indicate positive preclinical activity in animal models of SARS-CoV-2 transmission and favorable intranasal GLP toxicology and tolerability findings, with the program reported around 2021 to 2022 as preparing for IND submission and planned Phase 1 evaluation in healthy volunteers.
- Other names
- intranasal berdazimer sodiumberdazimer sodium intranasal formulation
Beyond the preview
Go deeper on SB019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB019.